oncnursingnews7h
Amezalpat Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
dermatologyadvisor1d
Rezpegaldesleukin Fast Tracked for Moderate to Severe Atopic Dermatitis
The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.
Targeted Oncology1d
FDA Fast Tracks Amezalpat for HCC Treatment
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Cancer Therapy Advisor1d
Amezalpat Gets Fast Track Designation for HCC
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Monthly Prescribing Reference2d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
manilatimes2d
Vera Bradley Continues Board Refreshment with Appointment of Andrew Meslow, Former CEO of Bath and Body Works
FORT WAYNE, Ind., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Vera Bradley (NASDAQ: VRA) (the "Company”) today announced the appointment of Andrew Meslow, former CEO of L Brands and Bath and Body Works, to the ...
Tempest Therapeutics granted FTD from FDA for amezalpat
Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...